Vestal Point Capital, LP - 31 Dec 2025 SCHEDULE 13G Report for Enliven Therapeutics, Inc. Common Stock, par value $0.001 per share (ELVN)

Filing Manager: Vestal Point Capital, LP
Reporting Manager: Vestal Point Capital, LP
Security: Enliven Therapeutics, Inc. Common Stock, par value $0.001 per share
Symbol: ELVN
Shares outstanding: 58,923,077 shares
Disclosed Ownership: 3,830,000 shares
Ownership: 6.5%
Form type: SCHEDULE 13G
Filing time: 17 Feb 2026, 16:07:16 UTC
Date of event: 31 Dec 2025
SEC: View on sec.gov

Reporting Managers (2)

Name	Ownership	Shares Owned	sole voting power	shared voting power	Signature	Title	CIK
Vestal Point Capital, LP	6.5%	3,830,000	0	3,830,000	/s/ Ryan Wilder	By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner
Ryan Wilder	6.5%	3,830,000	0	3,830,000	/s/ Ryan Wilder	Ryan Wilder, Individually